The incidence of lung cancer in Taiwan Province Province is the second in Asia, and targeted drug ROS 1 can save millions of patients.

Will watching TV definitely make you nearsighted? The two key reasons of medical exposure are driving north to urinate and acupuncture to improve overactive bladder. Yadong hospital's "individualized treatment goal" helps patients integrate into society and make them unable to work! Comprehensive care of rheumatoid arthritis can reduce future disability. Every year 1 1 month is the International Lung Cancer Prevention and Treatment Month. Dr. Chen Yumin, director of the General Chest Department of Taipei Rongzong, said that the mortality rate of lung cancer was the first in ten years in a row, and the incidence rate of lung cancer in Taiwan Province Province was the second in Asia. The probability of cancer cells metastasizing to the brain was extremely high, and it had become a "new national disease".

More than half of the patients were diagnosed with advanced stage.

Dr. Chen Yumin said that more than half of the patients in Taiwan Province Province were diagnosed as advanced, and 90% of them were non-small lung adenocarcinoma. Dr. Guo, Director of Lung Cancer Endoscopy Department of Linkou Chang Gung Hospital, said that the existing third-generation targeted drugs have been approved, breaking through the drug resistance limit, with a tumor remission rate of 40% and a tumor remission duration of 6 months, which has a good therapeutic effect on brain metastasis. Now the target drug ROS 1 is paid by medical insurance, which can save patients 6.5438+0.8 million yuan a year.

Director Guo explained that according to foreign research, for patients who have used the second-generation targeted drugs or are resistant to two or more targeted drugs, the tumor remission rate of the third-generation targeted drugs is nearly 40% regardless of whether they are combined with chemotherapy, and the tumor remission duration can be as high as nearly 6 months.

Moreover, compared with the first-generation targeted drugs, the third-generation ALK targeted drugs are more likely to penetrate the brain barrier and enter the brain to control tumors, and the effective rate for brain metastasis is over 50%. In patients who use more than two kinds of ALK targeted drugs, the duration of tumor remission can be as long as 65438 04.5 months.

At present, the third-generation ALK targeted drugs have been officially approved in Taiwan Province Province, which provides more treatment options for lung cancer patients who are resistant to the second-generation ALK targeted drugs.

Who: The incidence of lung cancer in Taiwan Province Province ranks 15 in the world and second in Asia.

According to WHO research, the incidence of lung cancer in Taiwan Province Province ranks 15 in the world, second only to North Korea in Asia. The incidence rate of women has even squeezed into the eighth place in the world, and lung cancer has become a "new national disease" in Taiwan Province Province! Chairman Chen Yumin shared that the number of lung cancer deaths reached a record high in 20 18, and according to the data, the onset age of lung cancer has declined, from 72 to 68 for men and from 65 for women in the past decade. Because the early symptoms of lung cancer are not obvious, more than half of them are diagnosed as advanced, and chemotherapy and targeted therapy will be given priority in treatment.

Third-generation ALK target drug approval reduces the burden on patients.

Director Guo said that lung adenocarcinoma is the majority of all lung cancer patients, and nearly 70% of lung adenocarcinoma patients have gene mutation, which is much higher than that in Europe and America. Nearly 55% patients have EGFR (epidermal growth factor receptor). If the test result is negative, other genetic tests will be carried out. In patients without EGFR mutation, nearly 10% had ALK (denatured lymphomanufacturing enzyme) gene mutation. It is suggested that cancer friends should screen ALK and ROS 1 (transmembrane receptor protein tyrosine kinase) genes at the same time after diagnosis, so as to shorten the detection process.

Cai, deputy executive director of Taiwan Province Cancer Foundation, said that after the approval of the third-generation target drug, patients have the choice of follow-up treatment, and ROS 1 target drug has further reduced the economic burden of patients' treatment through health insurance.

Title: ROS 1 Targeted Drugs, Dr. Chen Yumin, Director of General Chest Department of Taipei Rong, Third Generation Targeted Drugs, Lung Adenocarcinoma.